Transcript of Earnings Conference Call on Audited Standalone and Consolidated Financial Results for the Quarter and Year ended 31-03-2026
INDOCO · price
▲ positive · ▼ negative · ● neutral filings · teal = economic event · numbered = multiple that day (click to pick). Times IST.
Indoco Remedies reported Q4 FY26 results with standalone net revenues of INR 4,291 million (up 25.8% YoY) and consolidated revenues of INR 4,559 million (up 18.8% YoY). EBITDA margins improved significantly to 14.7% standalone and 10.9% consolidated, recovering from near-zero levels a year ago. International formulations drove growth with US business up 77.5%, Europe up 68.7%, and emerging markets up 134%. However, domestic business was muted due to poor seasonal conditions affecting anti-infectives and respiratory segments. Management flagged concerns about rising receivables (45% growth driven by emerging market credit periods), high debt levels of approximately INR 960 crore consolidated, and INR 24 crore forex loss on ECB loan. The company committed to repaying INR 140 crore annually for the next 3 years and expects no major CAPEX for 2 years. Ophthalmic business in India and Africa was hived off to Sunway to focus on core ethical business.
Positive turnaround in profitability after 6 quarters of losses is encouraging, but high debt levels and working capital pressures remain key concerns for shareholders. Management's debt reduction roadmap and tight CAPEX controls provide some visibility on deleveraging.